Meningococcal disease

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022
Global, Safety, IPV, Efficiency, CIC, National Medical Products Administration, RNA transfection, HFRS, HAV, Goldman Sachs, Industry, China International Capital Corporation, Stock exchange, Clinical trial, Mumps, Technology, CDC, Meningococcal disease, Vaccine, US, HPV, Research, International, SEHK, COVID-19, Food, Company, Rabies, NDA, Omicron, Science, Exploration, NMPA, Globe, COVID-19 vaccine, AIM, Culture, L.L.C, National, CTA, Honesty, HBV, CMOS, Public health, Coronavirus, Record, Marketing, GMP, Motherboard, Health, The Group, Program, 2000 Simpsonwood CDC conference, Infection, Pharmaceutical industry, Property management, PRC, Group, Limited

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

Outlook on the Meningococcal Vaccines Global Market to 2030 - Increasing Immunization Programs and Government Initiatives is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022
Infectious Diseases, Pharmaceutical, Health, Inactivated vaccine, Sanofi, Goal, NIP, ECDC, Meningitis Vaccine Project, Disease, Government, National Center for Immunization and Respiratory Diseases, Organization, WHO, Meningitis, MenAfriVac, Vaccine, FDA, Growth, Profile, Meningococcal disease, Incidence, Prevalence, Epidemic, CAGR, USD, Pharmaceutical industry, Meningococcal vaccine, Meningococcal vaccine, Serotype, EU, Meningococcal vaccine

The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%.

Key Points: 
  • The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%.
  • In addition, rising FDA approval for meningococcal vaccines is expected to boost the growth.
  • The increase in approval of novel vaccines is expected to improve meningococcal prevention which in turn, is anticipated to drive the market.
  • Initiatives undertaken by the government to combat the rising incidence of the disease are anticipated to boost the meningococcal vaccine market growth.

CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research

Retrieved on: 
Monday, April 25, 2022
Nature, DNA, Adenoviridae, HKEX, COVID-19, Meningococcal disease, Research, Life, R, Multilateralism, Group, CRM197, Trial of the century, Technology, Vaccine, Company, Infection, CanSino Biologics, History, Coronavirus, Public health, MCV4, Multimedia, SSE, RNA transfection, Pharmaceutical industry

This is the first major brand refresh of CanSinoBIO since its inception in 2009.

Key Points: 
  • This is the first major brand refresh of CanSinoBIO since its inception in 2009.
  • The blue color represents "technology" and the green color represents "life," embracing and complementing each other to depict the close relationship between technology and human life.
  • Sixty-nine years later, CanSinoBIO continues to uphold the scientific spirit by committing to continuous research and development (R&D) of innovative, high-quality and accessible vaccine products to protect human life.
  • Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines for China and global public health security.

CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research

Retrieved on: 
Monday, April 25, 2022
Nature, DNA, Adenoviridae, HKEX, COVID-19, Meningococcal disease, Research, Life, R, Multilateralism, Group, CRM197, Trial of the century, Technology, Vaccine, Company, Infection, CanSino Biologics, History, Coronavirus, Public health, MCV4, SSE, RNA transfection, Pharmaceutical industry

This is the first major brand refresh of CanSinoBIO since its inception in 2009.

Key Points: 
  • This is the first major brand refresh of CanSinoBIO since its inception in 2009.
  • The blue color represents "technology" and the green color represents "life," embracing and complementing each other to depict the close relationship between technology and human life.
  • Sixty-nine years later, CanSinoBIO continues to uphold the scientific spirit by committing to continuous research and development (R&D) of innovative, high-quality and accessible vaccine products to protect human life.
  • Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines for China and global public health security.

UNITY® Consortium launches Adolescent Immunization Action Week to get adolescents up to date on missed well visits and vaccinations

Retrieved on: 
Thursday, March 31, 2022
Cancer, Human, AIAW, Vaccination, Adolescence, HPV, Vaccine-preventable diseases, CDC, Parent, Public health, Adult, UNITY, Vaccine, Centers for Disease Control and Prevention, AAP, MPH, PSA, Pediatrics (journal), Health, Comcast, Industry, Clinton Foundation, Twitter, COVID-19, American Academy, Center, List of Facebook features, Child, Mark (given name), YouTube, Awareness, Instagram, Doctor of Philosophy, Meningococcal disease, Immunization, Facebook

NEWTOWN, Pa., March 31, 2022 /PRNewswire-PRWeb/ -- UNITY® Consortium is urging parents and healthcare providers take action this spring to get adolescents up to date on missed well visits and recommended vaccines during the inaugural Adolescent Immunization Action Week (April 4th- 8th). UNITY launched the initiative following a sharp decline in adolescent well visits and routine immunizations during the COVID-19 pandemic.

Key Points: 
  • UNITY Consortium is urging parents and healthcare providers take action this spring to get adolescents up to date on missed well visits and recommended vaccines during the inaugural Adolescent Immunization Action Week (April 4th- 8th).
  • NEWTOWN, Pa., March 31, 2022 /PRNewswire-PRWeb/ -- UNITY Consortium is urging parents and healthcare providers take action this spring to get adolescents up to date on missed well visits and recommended vaccines during the inaugural Adolescent Immunization Action Week (April 4th- 8th).
  • UNITY launched the initiative following a sharp decline in adolescent well visits and routine immunizations during the COVID-19 pandemic.
  • As one strong voice, Unity Consortium addresses the unique challenges surrounding adolescent and young adult health, prevention and immunization.

Worldwide Travel Vaccines Industry to 2027 - Featuring Sanofi Pasteur, Novartis and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, February 25, 2022
Other Travel, Pharmaceutical, Health, Travel, Risk, Travel, Awareness, Ministry, Yellow fever, COVID-19, Antibody, Disease, Molecular epidemiology, Vaccine, Infection, Ministry of Health (Saudi Arabia), Meningococcal disease, Vaccination, Incidence, Kingdom, Animal, Aquaculture, Polio, Health

Travel vaccines, also known as travel immunizations, are vaccines travelers can get before they visit certain regions across the globe which help protect them from serious diseases.

Key Points: 
  • Travel vaccines, also known as travel immunizations, are vaccines travelers can get before they visit certain regions across the globe which help protect them from serious diseases.
  • Travel vaccines work by exposing the body to a microorganism or parts of the microorganism of the disease it will protect against.
  • Other factors driving the demand for travel vaccines include increasing awareness levels, technological advancements and increasing incidence of life-threatening infectious diseases.
  • What are the major regions in the global travel vaccines market?

Worldwide Meningococcal Vaccines Industry to 2026 - Featuring Novartis, Pfizer and Sanofi Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 20, 2021
General Health, Pharmaceutical, Health, Infection, Frasier, Research, Disease, Industry, Military personnel, Meningitis, Adoption, Immunization, Spinal cord, Inactivated vaccine, Meningococcal disease, Antibody, Membrane, Nerve, Brain, Seizure, Growth, COVID-19, Bacteria, R, Prevalence, Vaccine, Pharmaceutical industry, Potash

The three main kinds of meningococcal vaccines include conjugate, polysaccharide and subcapsular meningococcal vaccines.

Key Points: 
  • The three main kinds of meningococcal vaccines include conjugate, polysaccharide and subcapsular meningococcal vaccines.
  • They are administered to infants, children and adults to immunize them against the invasive disease and target meningococcal bacteria A, B, C, W-135 and Y.
  • How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
  • What is the structure of the global meningococcal vaccines market and who are the key players?

DoSomething.org and National Foundation for Infectious Diseases Launch New Program to Educate Young People About the Importance of Meningococcal Disease Prevention

Retrieved on: 
Thursday, August 12, 2021
Meningococcal disease, Kidney, Multimedia, National Foundation for Infectious Diseases, Naphthoate synthase, Hearing loss, Program, CEO, Finger, Vaccination, Disease, MD, Vaccine-preventable diseases, COVID-19, Infection, The, Social change, Risk, Family, Ownership, Martindale: The Complete Drug Reference, DoSomething, View, Brain damage, Friends, NFID, Amputation, Diagnosis, Student, Vaccine, Pharmaceutical industry

To help equip young people with reliable information, DoSomething.org and the National Foundation for Infectious Diseases (NFID ) have launched the "Complete What's Missing" program, which aims to educate young people about meningococcal disease and the importance of prevention through vaccination.

Key Points: 
  • To help equip young people with reliable information, DoSomething.org and the National Foundation for Infectious Diseases (NFID ) have launched the "Complete What's Missing" program, which aims to educate young people about meningococcal disease and the importance of prevention through vaccination.
  • Young people age 16-23 years have an increased risk of meningococcal disease , but they also have the power to take an active role in increasing vaccination rates.
  • "We launched the 'Complete What's Missing' program just in time for high school and college students to return to campuses.
  • COVID-19 isn't the only disease that young people need to get vaccinated against to stay safe as they return to school this fall.

The National Meningitis Association Partners with Molly Ringwald to Urge Parents to Help Protect Their Teens Against Meningococcal Meningitis

Retrieved on: 
Thursday, May 20, 2021
Bacteria, Medical specialties, Clinical medicine, Meningococcal disease, Sepsis, Meningitis, Neisseria meningitidis, Sanofi

When my oldest daughter turned 16, my husband and I made sure she received the second dose of the MenACWY vaccine because we want to help protect her future," said Ringwald.

Key Points: 
  • When my oldest daughter turned 16, my husband and I made sure she received the second dose of the MenACWY vaccine because we want to help protect her future," said Ringwald.
  • "I was shocked to learn that around half of teens nationwide haven\'t received this second dose, which helps strengthen protection against meningococcal disease.1We need more awareness.
  • "5,10\nAs part ofThe 16 Vaccineinitiative, Ringwald and the NMA are sharing a public service announcement, which will start airing in June across the country.
  • The16Vaccine.org also offers an option for parents to sign up for reminders to schedule their teens\' 16-year vaccination visit.\nThe 16 Vaccineis a disease awareness educational initiative by the National Meningitis Association (NMA), in collaboration with Sanofi.

Insights on the Meningococcal Vaccine Global Market to 2026 - Featuring GlaxoSmithKline, Pfizer and Sanofi Among Others

Retrieved on: 
Tuesday, April 20, 2021
Medical specialties, Bacteria, Clinical medicine, Bacterial diseases, Vaccine-preventable diseases, Meningitis, Meningococcal disease, Sepsis, Neisseria meningitidis, MenAfriVac, Viral meningitis

In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics.

Key Points: 
  • In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics.
  • According to the Centers for Disease Control and Prevention (CDC), about 1.2 million cases of meningococcal meningitis are estimated to occur worldwide every year.
  • The government and regulatory authorities are taking initiatives to combat the increasing prevalence of meningitis are likely to drive the market growth.
  • North America led the market and had a significant revenue share of the market in 2019 which is followed by Europe.